Skip to main content

Advertisement

SpringerLink
Log in

A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This study aims to evaluate the clinical and radiological efficacy as well as safety profiles of Anbainuo, a recombinant human TNFRII:Fc fusion protein, combined with methotrexate (MTX) versus MTX alone or Anbainuo alone in the treatment of Chinese patients with moderate to severe rheumatoid arthritis (RA). In this 24-week, multicenter, double-blind, active comparator-controlled study, 396 RA patients were randomized into combination therapy group (Anbainuo plus MTX), Anbainuo group, or MTX group. Clinical response was assessed using the American College of Rheumatology (ACR)-N, ACR20, ACR50, ACR70, and van der Heijde modification of Sharp score, among which ACR-N and ACR20 were defined as primary major endpoints. After 24 weeks of treatment, the ACR-N in the combination therapy group (12.79 ± 9.24 %) was significantly higher than that in Anbainuo group (9.56 ± 11.16 %) and in MTX group (5.08 ± 11.1 %) (p = 0.00 and p = 0.00, respectively). Patients in Anbainuo group had significantly higher ACR-N than those in MTX group (p = 0.02). More patients in the combination therapy group (53.6 %) achieved ACR50 improvement response than those in the MTX group (30.8 %). ACR70 of combination therapy group (27.7 %) was significantly higher than that of Anbainuo group (15.8 %) and MTX group (7.70 %), with no significant difference between Anbainuo group and MTX group. DAS28-ESR in the combination therapy group was significantly reduced compared to either monotherapy groups. Moreover, DAS28-ESR was significantly lower in Anbainou group than in MTX group. The combination therapy group also showed significantly less radiographic progression than the MTX group (p = 0.03). The total adverse events (AE) in the combination group (40.9 %) was significantly higher than those in the MTX group (28.8 %) (p < 0.05). Anbainuo combined with MTX therapy can effectively control the disease activity and radiographic progression of RA, while the incidence of AE also increased compared to either Anbainuo or MTX.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Reference

  1. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117(2):244–279. doi:10.1016/j.pharmthera.2007.10.001

    Article  PubMed  CAS  Google Scholar 

  2. Feldmann M, Maini RN (2003) Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9(10):1245–1250. doi:10.1038/nm939

    Article  PubMed  CAS  Google Scholar 

  3. Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med Unbound 340(4):253–259

    Article  CAS  Google Scholar 

  4. Feldman M, Taylor P, Paleolog E, Brennan F, Maini R (1998) Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant Proc 30(8):4126–4127

    Article  PubMed  CAS  Google Scholar 

  5. Marzo-Ortega H, McGonagle D, O'Connor P et al (2001) Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 44(9):2112–2117

    Article  PubMed  CAS  Google Scholar 

  6. Murdaca G, Colombo B, Puppo F (2011) Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today 47(1):277, Barcelona, Spain: 1998

    PubMed  CAS  Google Scholar 

  7. Klarenbeek NB, Guler-Yuksel M, van der Kooij SM et al (2011) The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 70(6):1039–1046

    Article  PubMed  Google Scholar 

  8. Ruiz GV, Jobanputra P, Burls A et al (2011) Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2:CD007649

    Google Scholar 

  9. Pappas DA, Bathon JM, Hanicq D, Yasothan U, Kirkpatrick P (2009) Golimumab. Nat Rev Drug Discov 8(9):695–696

    Article  PubMed  CAS  Google Scholar 

  10. Hu D, Bao C, Chen S et al (2009) A comparison study of a recombinant tumor necrosis factor receptor: Fc fusion protein (rhTNFR: Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China. Rheumatol Int 29(3):297–303

    Article  PubMed  CAS  Google Scholar 

  11. Moreland LW, Schiff MH, Baumgartner SW et al (1999) Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 130(6):478–486

    PubMed  CAS  Google Scholar 

  12. Goffe B, Cather JC (2003) Etanercept: an overview. J Am Acad Dermatol 49(2 Suppl):S105–S111. doi:10.1016/mjd.2003.554

    Article  PubMed  Google Scholar 

  13. Kameda H, Ueki Y, Saito K et al (2010) Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol 20(6):531–538. doi:10.1007/s10165-010-0324-4

    Article  PubMed  CAS  Google Scholar 

  14. Knevel R, Schoels M, Huizinga T et al (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69(6):987

    Article  PubMed  CAS  Google Scholar 

  15. Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L (2010) Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther (0):1-12

  16. Bathon JM, Fleischmann RM, Van der Heijde D et al (2006) Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 33(2):234

    PubMed  CAS  Google Scholar 

  17. Chen S, Chen SL, Huang F et al (2010) A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of Etanercept in Chinese subjects with active rheumatoid arthritis receiving methotrexate. Chin J Rheumatol 7:450–455

    Google Scholar 

  18. Genovese MC, Bathon JM, Martin RW et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two years radiographic and clinical outcomes. Arthritis Rheum 46(6):1443–1450

    Article  PubMed  CAS  Google Scholar 

  19. Klareskog L, van der Heijde D, de Jager JP et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675–681

    Article  PubMed  CAS  Google Scholar 

  20. Nam J, Winthrop K, Van Vollenhoven R et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69(6):976

    Article  PubMed  CAS  Google Scholar 

  21. Bathon JM, Martin RW, Fleischmann RM et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med Unbound 343(22):1586–1593

    Article  CAS  Google Scholar 

  22. Emery P, Breedveld FC, Hall S et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372(9636):375–382

    Article  PubMed  CAS  Google Scholar 

  23. van der Heijde D, Klareskog L, Rodriguez-Valverde V et al (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54(4):1063–1074

    Article  PubMed  Google Scholar 

  24. Kremer JM, Weinblatt ME, Bankhurst AD et al (2003) Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 48(6):1493–1499

    Article  PubMed  CAS  Google Scholar 

  25. van der Heijde D, Klareskog L, Landewé R et al (2007) Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56(12):3928–3939

    Article  PubMed  Google Scholar 

  26. Kameda H, Ueki Y, Saito K et al (2010) Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol 20(6):531–538

    Article  PubMed  CAS  Google Scholar 

  27. Emery P, Breedveld F, van der Heijde D et al (2010) Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 62(3):674–682

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by Hisun Pharmaceutical. We appreciated doctor Zi-qian Lin for assessing SHARP score, and Doctor Qiong Fu for key revising. This study was supported by the Hisun Pharmaceutical (ChiCTR: 2006 L04778).

Disclosure

None.

Author information

Authors and Affiliations

  1. Renji Hospital, School of Medicine, Affiliated to Shanghai JiaoTong University, Shanghai, China

    Xiao-Xiang Chen, Qing Dai & Chun-De Bao

  2. The Union Hospital, Affiliated to Tongji University, Hubei Province, China

    An-Bin Huang

  3. Second Hospital, Affiliated to Zhejiang University, Zhejiang Province, China

    Hua-Xiang Wu

  4. Changhai Hospital, Affiliated to Second Military Medical University, Shanghai, China

    Dong-Bao Zhao

  5. Qilu Hospital, Affiliated to Shandong University, Shandong Province, China

    Xing-Fu Li

  6. Tongji Hospital, Affiliated to Tongji University, Hubei Province, China

    Shao-Xian Hu

  7. Huaxi Hospital, Affiliated to Sichuan University, Sichuan Province, China

    Nan-Ping Yang

  8. The Third Hospital, Affiliated to Zhongshan Medical University, Guangdong Province, China

    Yi Tao

  9. The First Hospital, Affiliated to Anhui medical University, Anhui Province, China

    Jian-Hua Xu

  10. Zhongshan Hospital, Affiliated to Fudan University, Shanghai, China

    Lin-Di Jiang

Authors
  1. Xiao-Xiang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qing Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. An-Bin Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hua-Xiang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dong-Bao Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xing-Fu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shao-Xian Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nan-Ping Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yi Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jian-Hua Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lin-Di Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Chun-De Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chun-De Bao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, XX., Dai, Q., Huang, AB. et al. A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis. Clin Rheumatol 32, 99–108 (2013). https://doi.org/10.1007/s10067-012-2096-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-012-2096-z

Keywords

Search

Navigation